AEON Biopharma Net Income
| AEON Stock | 0.96 0.01 1.58% |
As of the 13th of February 2026, AEON Biopharma shows the risk adjusted performance of 0.0411, and Mean Deviation of 4.3. AEON Biopharma technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
AEON Biopharma's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing AEON Biopharma's valuation are provided below:We have found one hundred twenty available fundamental signals for AEON Biopharma, which can be analyzed and compared to other ratios and to its rivals. Self-guided Investors are advised to validate AEON Biopharma's prevailing fundamentals against the trend between 2010 and 2026 to make sure the company can sustain itself in the future. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. | Last Reported | Projected for Next Year | ||
| Net Income From Continuing Ops | 37.8 M | 39.7 M | |
| Net Loss | -47.3 M | -44.9 M | |
| Net Income | 37.8 M | 39.7 M | |
| Net Income Per Share | 84.01 | 79.81 | |
| Net Income Per E B T | 1.07 | 0.95 |
AEON | Net Income | Build AI portfolio with AEON Stock |
Evaluating AEON Biopharma's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into AEON Biopharma's fundamental strength.
Latest AEON Biopharma's Net Income Growth Pattern
Below is the plot of the Net Income of AEON Biopharma over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in AEON Biopharma financial statement analysis. It represents the amount of money remaining after all of AEON Biopharma operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is AEON Biopharma's Net Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in AEON Biopharma's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 42.01 M | 10 Years Trend |
|
Net Income |
| Timeline |
AEON Net Income Regression Statistics
| Arithmetic Mean | 77,821,543 | |
| Geometric Mean | 110,638,825 | |
| Coefficient Of Variation | 191.60 | |
| Mean Deviation | 111,880,538 | |
| Median | 172,920,000 | |
| Standard Deviation | 149,103,553 | |
| Sample Variance | 22231.9T | |
| Range | 557.6M | |
| R-Value | (0.63) | |
| Mean Square Error | 14315.5T | |
| R-Squared | 0.40 | |
| Significance | 0.01 | |
| Slope | (18,588,485) | |
| Total Sum of Squares | 355709.9T |
AEON Net Income History
Other Fundumenentals of AEON Biopharma
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
AEON Biopharma Net Income component correlations
AEON Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for AEON Biopharma is extremely important. It helps to project a fair market value of AEON Stock properly, considering its historical fundamentals such as Net Income. Since AEON Biopharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of AEON Biopharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of AEON Biopharma's interrelated accounts and indicators.
Click cells to compare fundamentals
Will Biotechnology sector continue expanding? Could AEON diversify its offerings? Factors like these will boost the valuation of AEON Biopharma. If investors know AEON will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every AEON Biopharma data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Investors evaluate AEON Biopharma using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating AEON Biopharma's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause AEON Biopharma's market price to deviate significantly from intrinsic value.
Understanding that AEON Biopharma's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether AEON Biopharma represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, AEON Biopharma's market price signifies the transaction level at which participants voluntarily complete trades.
AEON Biopharma 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to AEON Biopharma's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of AEON Biopharma.
| 11/15/2025 |
| 02/13/2026 |
If you would invest 0.00 in AEON Biopharma on November 15, 2025 and sell it all today you would earn a total of 0.00 from holding AEON Biopharma or generate 0.0% return on investment in AEON Biopharma over 90 days. AEON Biopharma is related to or competes with Cingulate, Cellectar Biosciences, Bolt Biotherapeutics, Marker Therapeutics, OSR Holdings, Clene, and Abpro Holdings. AEON Biopharma is entity of United States More
AEON Biopharma Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure AEON Biopharma's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess AEON Biopharma upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 5.9 | |||
| Information Ratio | 0.0264 | |||
| Maximum Drawdown | 33.74 | |||
| Value At Risk | (8.65) | |||
| Potential Upside | 10.34 |
AEON Biopharma Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for AEON Biopharma's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as AEON Biopharma's standard deviation. In reality, there are many statistical measures that can use AEON Biopharma historical prices to predict the future AEON Biopharma's volatility.| Risk Adjusted Performance | 0.0411 | |||
| Jensen Alpha | 0.1615 | |||
| Total Risk Alpha | (0.29) | |||
| Sortino Ratio | 0.0267 | |||
| Treynor Ratio | 0.2415 |
AEON Biopharma February 13, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0411 | |||
| Market Risk Adjusted Performance | 0.2515 | |||
| Mean Deviation | 4.3 | |||
| Semi Deviation | 5.26 | |||
| Downside Deviation | 5.9 | |||
| Coefficient Of Variation | 2504.34 | |||
| Standard Deviation | 5.97 | |||
| Variance | 35.66 | |||
| Information Ratio | 0.0264 | |||
| Jensen Alpha | 0.1615 | |||
| Total Risk Alpha | (0.29) | |||
| Sortino Ratio | 0.0267 | |||
| Treynor Ratio | 0.2415 | |||
| Maximum Drawdown | 33.74 | |||
| Value At Risk | (8.65) | |||
| Potential Upside | 10.34 | |||
| Downside Variance | 34.84 | |||
| Semi Variance | 27.63 | |||
| Expected Short fall | (4.96) | |||
| Skewness | 0.4472 | |||
| Kurtosis | 1.44 |
AEON Biopharma Backtested Returns
AEON Biopharma appears to be dangerous, given 3 months investment horizon. AEON Biopharma secures Sharpe Ratio (or Efficiency) of 0.0537, which signifies that the company had a 0.0537 % return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for AEON Biopharma, which you can use to evaluate the volatility of the firm. Please makes use of AEON Biopharma's risk adjusted performance of 0.0411, and Mean Deviation of 4.3 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, AEON Biopharma holds a performance score of 4. The firm shows a Beta (market volatility) of 0.95, which signifies possible diversification benefits within a given portfolio. AEON Biopharma returns are very sensitive to returns on the market. As the market goes up or down, AEON Biopharma is expected to follow. Please check AEON Biopharma's treynor ratio and the relationship between the semi variance and price action indicator , to make a quick decision on whether AEON Biopharma's price patterns will revert.
Auto-correlation | -0.43 |
Modest reverse predictability
AEON Biopharma has modest reverse predictability. Overlapping area represents the amount of predictability between AEON Biopharma time series from 15th of November 2025 to 30th of December 2025 and 30th of December 2025 to 13th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of AEON Biopharma price movement. The serial correlation of -0.43 indicates that just about 43.0% of current AEON Biopharma price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.43 | |
| Spearman Rank Test | 0.1 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
AEON Net Interest Income
Based on the recorded statements, AEON Biopharma reported net income of 42.01 M. This is 87.69% lower than that of the Biotechnology sector and 40.03% lower than that of the Health Care industry. The net income for all United States stocks is 92.64% higher than that of the company.
AEON Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses AEON Biopharma's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of AEON Biopharma could also be used in its relative valuation, which is a method of valuing AEON Biopharma by comparing valuation metrics of similar companies.AEON Biopharma is currently under evaluation in net income category among its peers.
AEON Fundamentals
| Return On Asset | -1.29 | ||||
| Current Valuation | 38.64 M | ||||
| Shares Outstanding | 11.64 M | ||||
| Shares Owned By Insiders | 19.10 % | ||||
| Shares Owned By Institutions | 12.57 % | ||||
| Number Of Shares Shorted | 37.34 K | ||||
| Price To Sales | 97.16 X | ||||
| EBITDA | (27.73 M) | ||||
| Net Income | 42.01 M | ||||
| Total Debt | 12.96 M | ||||
| Book Value Per Share | (1.37) X | ||||
| Cash Flow From Operations | (20.29 M) | ||||
| Short Ratio | 0.11 X | ||||
| Earnings Per Share | (13.91) X | ||||
| Target Price | 7.2 | ||||
| Beta | 0.75 | ||||
| Market Capitalization | 10.95 M | ||||
| Total Asset | 3.14 M | ||||
| Retained Earnings | (431.6 M) | ||||
| Working Capital | (12.56 M) | ||||
| Net Asset | 3.14 M |
About AEON Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze AEON Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of AEON Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of AEON Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with AEON Biopharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if AEON Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AEON Biopharma will appreciate offsetting losses from the drop in the long position's value.Moving against AEON Stock
| 0.81 | DWTX | Dogwood Therapeutics | PairCorr |
| 0.74 | KURA | Kura Oncology | PairCorr |
| 0.73 | ABP | Abpro Holdings | PairCorr |
| 0.71 | IMRN | Immuron Ltd ADR | PairCorr |
| 0.7 | GNLX | Genelux Common | PairCorr |
The ability to find closely correlated positions to AEON Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace AEON Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back AEON Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling AEON Biopharma to buy it.
The correlation of AEON Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as AEON Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if AEON Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for AEON Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out To learn how to invest in AEON Stock, please use our How to Invest in AEON Biopharma guide.You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Will Biotechnology sector continue expanding? Could AEON diversify its offerings? Factors like these will boost the valuation of AEON Biopharma. If investors know AEON will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every AEON Biopharma data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Investors evaluate AEON Biopharma using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating AEON Biopharma's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause AEON Biopharma's market price to deviate significantly from intrinsic value.
Understanding that AEON Biopharma's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether AEON Biopharma represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, AEON Biopharma's market price signifies the transaction level at which participants voluntarily complete trades.